Taking people in GermanyPhase 1/2
Tests MB-CART2019.1 cell therapy in people with hard-to-treat multiple sclerosis
Tests MB-CART2019.1 cell therapy in adults with hard-to-treat multiple sclerosis.
Key facts
- Who runs it
- Miltenyi Biomedicine GmbH
- Where
- Berlin and Hamburg, GermanySee the 2 sites
- Trial code
- Registry title
- MB-CART2019.1 in refractory MS
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 25 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 30 Dec 2030
- Type of study
- Interventional
- Record updated
- 18 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple sclerosis that has not responded to treatment. It tests MB-CART2019.1.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Refractory multiple sclerosis
Main reasons for not taking part
- Healthy volunteers cannot join
Where in Germany
- Charite Universitaetsmedizin Berlin KöRBerlin, GermanyTaking people
- University Medical Center Hamburg-EppendorfHamburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests MB-CART2019.1 cell therapy in people with hard-to-treat multiple sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 September 2026